1
|
Gorain B, Karmakar V, Sarkar B, Dwivedi M, Leong JTL, Toh JH, Seah E, Ling KY, Chen KY, Choudhury H, Pandey M. Biomacromolecule-based nanocarrier strategies to deliver plant-derived bioactive components for cancer treatment: A recent review. Int J Biol Macromol 2023; 253:126623. [PMID: 37657573 DOI: 10.1016/j.ijbiomac.2023.126623] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 08/25/2023] [Accepted: 08/29/2023] [Indexed: 09/03/2023]
Abstract
The quest for safe chemotherapy has attracted researchers to explore anticancer potential of herbal medicines. Owing to upsurging evidence of herbal drug's beneficial effects, hopes are restored for augmenting survival rates in cancer patients. However, phytoconstituents confronted severe limitations in terms of poor absorption, low-stability, and low bioavailability. Along with toxicity issues associated with phytoconstituents, quality control and limited regulatory guidance also hinder the prevalence of herbal medicines for cancer therapy. Attempts are underway to exploit nanocarriers to circumvent the limitations of existing and new herbal drugs, where biological macromolecules (e.g., chitosan, hyaluronic acid, etc.) are established highly effective in fabricating nanocarriers and cancer targeting. Among the discussed nanocarriers, liposomes and micelles possess properties to cargo hydro- and lipophilic herbal constituents with surface modification for targeted delivery. Majorly, PEG, transferrin and folate are utilized for surface modification to improve bioavailability, circulation time and targetability. The dendrimer and carbon nanotubes responded in high-loading efficiency of phytoconstituent; whereas, SLN and nanoemulsions are suited carriers for lipophilic extracts. This review emphasized unveiling the latent potential of herbal drugs along with discussing on extended benefits of nanocarriers-based delivery of phytoconstituents for safe cancer therapy owing to enhanced clinical and preclinical outcomes without compromising safety.
Collapse
Affiliation(s)
- Bapi Gorain
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, India.
| | - Varnita Karmakar
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, India
| | - Biswatrish Sarkar
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, India
| | - Monika Dwivedi
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, India
| | - Janelle Tsui Lyn Leong
- School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya 47500, Selangor, Malaysia
| | - Jing Hen Toh
- School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya 47500, Selangor, Malaysia
| | - Even Seah
- School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya 47500, Selangor, Malaysia
| | - Kang Yi Ling
- School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya 47500, Selangor, Malaysia
| | - Kah Yee Chen
- School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya 47500, Selangor, Malaysia
| | - Hira Choudhury
- Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
| | - Manisha Pandey
- Department of Pharmaceutical Sciences, Central University of Haryana, SSH 17, Jant, Haryana 123031, India.
| |
Collapse
|
2
|
Yun M, Yu M, Duggirala K, Lee K, Jo A, Seah E, Kim C, Cho B. MA07.08 JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Yun M, Yu M, Duggirala K, Lee K, Lim S, Jo A, Seah E, Kim C, Cho B. 999P JIN-A02, a fourth-generation, highly effective tyrosine kinase inhibitor with intracranial activity, targeting EGFR C797S mutations in NSCLC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Yong WP, Goh BC, Soo RA, Toh HC, Ethirajulu K, Wood J, Novotny-Diermayr V, Lee SC, Yeo WL, Chan D, Lim D, Seah E, Lim R, Zhu J. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol 2011; 22:2516-2522. [PMID: 21385886 DOI: 10.1093/annonc/mdq784] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The objective of this study was to assess the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SB939, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced solid malignancies. PATIENTS AND METHODS Dose-escalating cohorts of three to six patients received SB939 orally thrice weekly for 3 weeks in a 4-week cycle. Acetylated histone H3 (acH3) was measured in peripheral blood mononuclear cells (PBMCs). RESULTS Thirty patients treated at one of five doses (10-80 mg/day) received 79 cycles of SB939 (range, 1-12 cycles). Dose-limiting toxic effects were fatigue, hypokalemia, troponin T elevation, and QTc prolongation. Peak plasma concentration (C(max)) and area under the concentration-time curve extrapolated to infinity increased dose proportionally. The MTD of SB939 was 80 mg/day. The mean elimination half-life and oral clearance of SB939 were 7.2 ± 0.6 h and 53.0 ± 8.5 l/h, respectively, with no substantial accumulation on day 15. An increase in acH3 was observed at hour 3 and correlated with dose and C(max). Stable disease was seen in several tumor types treated at ≥40 mg. HDAC inhibition was consistently observed at 60 mg, the recommended dose. CONCLUSIONS SB939 can be safely administered at the recommended dose and reaches plasma levels that strongly inhibit HDAC in PBMCs. These data support further efficacy studies of SB939.
Collapse
Affiliation(s)
- W P Yong
- Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Hospital
| | - B C Goh
- Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Hospital.
| | - R A Soo
- Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Hospital
| | - H C Toh
- Department of Medical Oncology, National Cancer Centre
| | | | - J Wood
- S*BIO Pte Ltd, Singapore, Singapore
| | | | - S C Lee
- Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Hospital
| | - W L Yeo
- Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Hospital
| | - D Chan
- Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Hospital
| | - D Lim
- Department of Medical Oncology, National Cancer Centre
| | - E Seah
- Department of Haematology-Oncology, National University Hospital
| | - R Lim
- Department of Haematology-Oncology, National University Hospital
| | - J Zhu
- S*BIO Pte Ltd, Singapore, Singapore
| |
Collapse
|
5
|
Yong W, Goh B, Toh H, Soo R, Diermayr V, Goh A, Ethirajulu K, Lee S, Seah E, Zhu J. Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2560] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2560 Background: SB939 is a novel orally bioavailable inhibitor of class 1 and 2 histone deacetylases. We conducted a phase I study to assess the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics and preliminary efficacy of SB939 in patients with advanced solid malignancies. Methods: SB939 was administered orally every other day 3 times a week for 3 consecutive weeks, in a 4-week cycle. Cohorts of patient were treated with escalating doses of SB939 starting from 10 mg. PK and PD (Acetylated Histone 3 in PBMCs) samples were collected in the first cycle. Results: 31 patients were enrolled at 10 mg (n=3), 20 mg (4), 40 mg (8), 60 mg (10) and 80 mg (6). The median number of treatment cycles received was 3.6. Fatigue, elevation of troponin T and QTc prolongation were the observed dose-limiting toxicities (DLT). At 80mg, one patient each (3/6) experienced a DLT of grade 3 fatigue, grade 3 asymptomatic elevation of troponin T and grade 3 QTc prolongation respectively. All DLTs were reversible and no treatment mortality was observed. Grade 1–2 fatigue occurred in 56% of patients occurring mainly at the 4th week, and 37% of pts had G1–2 anorexia. Grade 3–4 thrombocytopenia was observed in 2 patients at 60 mg at cycles 1 and 6 of treatment. SB939 was rapidly absorbed reaching Tmax between 1–3 h after ingestion, and mean elimination half-life and oral clearance of SB939 were 7.2 + 0.6 hrs and 53 + 8.5 L/h respectively. Cmax and AUC (0-∞) were dose-proportionally increased at this dose range. There was no substantial accumulation of SB939 on day 15 following repeated dosing. Concentrations above IC50 of SB939 for HDAC I was reached at all doses. Acetylation of H3 was dose dependent and consistent at 60mg. Of the 13 patients evaluable for response, stable disease was seen in 1 patient with follicular thyroid carcinoma and 1 with hepatocellular carcinoma for 51 and 164 days respectively. Conclusions: SB939 has similar toxicity profiles as that of other HDAC inhibitors and a favorable PK/PD profile. The MTD of SB939 in this regimen was 80 mg and 60mg is the recommended dose, at which acetylation of H3 is consistently observed. Further phase 2 studies with SB939 in specific indications are being planned. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- W. Yong
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - B. Goh
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - H. Toh
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - R. Soo
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - V. Diermayr
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - A. Goh
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - K. Ethirajulu
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - S. Lee
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - E. Seah
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| | - J. Zhu
- National University Health System, Singapore; National Cancer Center, Singapore; S*BIO Pte Ltd, Singapore
| |
Collapse
|
6
|
Yong W, Goh B, Ethirajulu K, Yeo P, Otheris O, Chao S, Soo R, Yeo W, Seah E, Zhu J. 413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72347-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|